Retatrutide reached 28.3% weight loss but remains unapproved

What happened

Participants on the 12 mg dose lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, and 45.3% achieved at least 30% weight loss, a magnitude long associated with bariatric surgery.

The trial enrolled 2,339 adults with obesity or overweight with weight-related conditions. Full results, including a 30.3% figure at 104 weeks in a higher-BMI extension cohort, were presented at the ADA Scientific Sessions in June 2026. Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) were the most common adverse events, mostly during dose escalation. The company-reported topline also flagged favorable movement on several heart-health measures: waist size, non-HDL cholesterol, triglycerides, systolic pressure, and hsCRP all improved from baseline.

What it means

Lilly's own headline called the results powerful, the company's characterization, not an independent assessment. Either way, it moves "bariatric-level results from a medication" from concept to a concrete, dated topline, and it explains the questions patients are now asking about retatrutide.

It also raises the practical bar: 20-30% weight loss on a drug requires the same nutrition, muscle-preservation, and monitoring infrastructure that surgery programs already run.

What it does not mean

Retatrutide is not approved and cannot be legally prescribed or compounded; the FDA said so explicitly in its June 15, 2026 safety communication. Topline numbers are company-reported and not yet peer-reviewed in full. Nothing here means a current GLP-1 patient should wait for or switch toward an unapproved drug.